Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03796676




Registration number
NCT03796676
Ethics application status
Date submitted
4/01/2019
Date registered
8/01/2019
Date last updated
13/04/2022

Titles & IDs
Public title
JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
Scientific title
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 CO-ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Secondary ID [1] 0 0
JADE TEEN
Secondary ID [2] 0 0
B7451036
Universal Trial Number (UTN)
Trial acronym
JADE TEEN
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Atopic Dermatitis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - PF-04965842
Treatment: Drugs - PF04965842

Placebo comparator: Placebo - Placebo

Experimental: PF-04965842 100 mg QD - active

Experimental: PF-04965842 200 mg QD - active


Treatment: Drugs: Placebo
Placebo

Treatment: Drugs: PF-04965842
100 mg QD

Treatment: Drugs: PF04965842
200 mg QD
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' (0) or 'Almost Clear' (1) and =2 Points Improvement From Baseline at Week 12
Timepoint [1] 0 0
Baseline to Week 12
Primary outcome [2] 0 0
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response = 75% Improvement From Baseline at Week 12
Timepoint [2] 0 0
Baseline to Week 12
Secondary outcome [1] 0 0
Percentage of Participants Achieving =4 Points Improvement From Baseline in Peak Pruritis Numeric Rating Scale (PP-NRS) for Severity of Pruritus at Weeks 2, 4 and 12
Timepoint [1] 0 0
Baseline, Weeks 2, 4 and 12
Secondary outcome [2] 0 0
Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) at Week 12
Timepoint [2] 0 0
Baseline to Week 12
Secondary outcome [3] 0 0
Percentage of Participants Achieving IGA Response of 'Clear' or 'Almost Clear' and =2 Points Improvement From Baseline at All Scheduled Time Points Except Week 12
Timepoint [3] 0 0
Baseline, Weeks 2, 4 and 8
Secondary outcome [4] 0 0
Percentage of Participants Achieving EASI Response = 75% Improvement From Baseline at All Scheduled Time Points Except Week 12
Timepoint [4] 0 0
Baseline, Weeks 2, 4 and 8
Secondary outcome [5] 0 0
Percentage of Participants Achieving EASI Response = 50% Improvement From Baseline
Timepoint [5] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [6] 0 0
Percentage of Participants Achieving EASI Response = 90% Improvement From Baseline
Timepoint [6] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [7] 0 0
Percentage of Participants Achieving EASI Response =100% Improvement From Baseline
Timepoint [7] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [8] 0 0
Percent Change From Baseline in EASI Score
Timepoint [8] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [9] 0 0
Percentage of Participants Achieving =4 Points Improvement From Baseline in PP-NRS for Severity of Pruritus at All Scheduled Time Points Other Than Weeks 2, 4 and 12
Timepoint [9] 0 0
Baseline, Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Secondary outcome [10] 0 0
Time to First Achieve =4 Points Improvement From Baseline in PP-NRS for Severity of Pruritus
Timepoint [10] 0 0
Baseline to Week 16
Secondary outcome [11] 0 0
Percent Change From Baseline in PP-NRS for Severity of Pruritus
Timepoint [11] 0 0
Baseline, Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
Secondary outcome [12] 0 0
Change From Baseline in Percentage Body Surface Area (BSA)
Timepoint [12] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [13] 0 0
Percent Change From Baseline in Percentage BSA
Timepoint [13] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [14] 0 0
Percentage of Participants Achieving Percentage BSA < 5% at Week 12
Timepoint [14] 0 0
Baseline to Week 12
Secondary outcome [15] 0 0
Percentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response = 50% Improvement From Baseline
Timepoint [15] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [16] 0 0
Percentage of Participants Achieving SCORAD Response = 75% Improvement From Baseline
Timepoint [16] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [17] 0 0
Change From Baseline in SCORAD Total Score
Timepoint [17] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [18] 0 0
Percent Change From Baseline in SCORAD Total Score
Timepoint [18] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [19] 0 0
Change From Baseline in SCORAD Subjective Visual Analogue Scale (VAS) of Sleep Loss
Timepoint [19] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [20] 0 0
Percent Change From Baseline in SCORAD Subjective VAS of Sleep Loss
Timepoint [20] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [21] 0 0
Number of Days When a Corticosteroid Not Used up to Day 88
Timepoint [21] 0 0
Baseline to Day 88
Secondary outcome [22] 0 0
Change From Baseline in Children's Dermatology Life Quality Index (DLQI)
Timepoint [22] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [23] 0 0
Percentage of Participants With =2.5 Points at Baseline and Achieving =2.5 Points Improvement From Baseline in Children's DLQI
Timepoint [23] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [24] 0 0
Change From Baseline in Anxiety of Hospital Anxiety and Depression Scale (HADS)
Timepoint [24] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [25] 0 0
Change From Baseline in Depression of HADS
Timepoint [25] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [26] 0 0
Change From Baseline in Patient-Oriented Eczema Measure (POEM)
Timepoint [26] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [27] 0 0
Change From Baseline in Dermatitis Family Impact (DFI) at Week 12
Timepoint [27] 0 0
Baseline to Week 12
Secondary outcome [28] 0 0
Change From Baseline in Patient Global Assessment (PtGA)
Timepoint [28] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [29] 0 0
Percentage of Participants With =2 Points at Baseline and Achieving 'Clear' or 'Almost Clear' and =2 Points Improvement From Baseline in PtGA
Timepoint [29] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [30] 0 0
Change From Baseline in EuroQol Quality of Life 5-Dimension Youth Scale (EQ-5D-Y) VAS Score
Timepoint [30] 0 0
Baseline, Weeks 2, 4, 8 and 12
Secondary outcome [31] 0 0
Change From Baseline in Pediatric Functional Assessment of Chronic Illness Therapy Fatigue Scale (Peds-FACIT-F) at Week 12
Timepoint [31] 0 0
Baseline to Week 12
Secondary outcome [32] 0 0
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Timepoint [32] 0 0
16 weeks
Secondary outcome [33] 0 0
Number of Participants With Serious Adverse Events (SAEs)
Timepoint [33] 0 0
16 weeks
Secondary outcome [34] 0 0
Number of Participants Who Discontinued From the Study Due to TEAEs
Timepoint [34] 0 0
16 weeks
Secondary outcome [35] 0 0
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
Timepoint [35] 0 0
16 weeks
Secondary outcome [36] 0 0
Number of Participants With Electrocardiogram (ECG) Data Meeting Prespecified Criteria
Timepoint [36] 0 0
16 weeks
Secondary outcome [37] 0 0
Categorization of Vital Signs Data Meeting Prespecified Criteria
Timepoint [37] 0 0
16 weeks
Secondary outcome [38] 0 0
Fold Increase of Immunoglobulin G (IgG) Concentrations Against Specific Vaccine Antigens at 4 Weeks Post-Vaccination
Timepoint [38] 0 0
4 weeks post-vaccination with Tdap (Week 12)
Secondary outcome [39] 0 0
Plasma PF-04965842 Concentration at Week 8
Timepoint [39] 0 0
2 hours pre-dose at Week 8
Secondary outcome [40] 0 0
Plasma PF-04965842 Concentration at Week 12
Timepoint [40] 0 0
2 hours post-dose at Week 12

Eligibility
Key inclusion criteria
* Aged between 12 and to 17 with a minimum body weight of 40 kg
* Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (>= the following scores: BSA 10%, IGA 3, EASI 16, Pruritus NRS severity 4)
Minimum age
12 Years
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation
* Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study
* Prior treatment with JAK inhibitors
* Other active non-AD inflammatory skin diseases or conditions affecting skin
* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, malignancies, current or history of certain infections, lymphoproliferative disorders and other medical conditions at the discretion of the investigator
* Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
18/02/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
8/04/2020
Sample size
Target
Accrual to date
Final
287
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC, (vic)VIC
Recruitment hospital [1] 0 0
Australian Clinical Research Network - Maroubra
Recruitment hospital [2] 0 0
The Skin Hospital - Westmead
Recruitment hospital [3] 0 0
The Skin Centre - Benowa
Recruitment hospital [4] 0 0
Sinclair Dermatology - East Melbourne
Recruitment hospital [5] 0 0
The Royal Children's Hospital - Parkville
Recruitment postcode(s) [1] 0 0
2035 - Maroubra
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4217 - Benowa
Recruitment postcode(s) [4] 0 0
3002 - East Melbourne
Recruitment postcode(s) [5] 0 0
3052 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
Nevada
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Oklahoma
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Virginia
Country [18] 0 0
United States of America
State/province [18] 0 0
West Virginia
Country [19] 0 0
United States of America
State/province [19] 0 0
Wisconsin
Country [20] 0 0
China
State/province [20] 0 0
Fujian
Country [21] 0 0
China
State/province [21] 0 0
Hunan
Country [22] 0 0
China
State/province [22] 0 0
Jiangxi
Country [23] 0 0
China
State/province [23] 0 0
Shandong
Country [24] 0 0
China
State/province [24] 0 0
Shanghai
Country [25] 0 0
China
State/province [25] 0 0
Yunnan
Country [26] 0 0
China
State/province [26] 0 0
Zhejiang
Country [27] 0 0
Czechia
State/province [27] 0 0
Kutna Hora
Country [28] 0 0
Czechia
State/province [28] 0 0
Nachod
Country [29] 0 0
Czechia
State/province [29] 0 0
Praha 2
Country [30] 0 0
Czechia
State/province [30] 0 0
Praha
Country [31] 0 0
Czechia
State/province [31] 0 0
Svitavy
Country [32] 0 0
Germany
State/province [32] 0 0
NRW
Country [33] 0 0
Germany
State/province [33] 0 0
Bad Bentheim
Country [34] 0 0
Germany
State/province [34] 0 0
Bonn
Country [35] 0 0
Germany
State/province [35] 0 0
Hamburg
Country [36] 0 0
Germany
State/province [36] 0 0
Muenster
Country [37] 0 0
Hungary
State/province [37] 0 0
Budapest
Country [38] 0 0
Hungary
State/province [38] 0 0
Gyöngyös
Country [39] 0 0
Hungary
State/province [39] 0 0
Gyor
Country [40] 0 0
Hungary
State/province [40] 0 0
Kaposvár
Country [41] 0 0
Hungary
State/province [41] 0 0
Miskolc
Country [42] 0 0
Hungary
State/province [42] 0 0
Püspökladány
Country [43] 0 0
Italy
State/province [43] 0 0
Milano
Country [44] 0 0
Japan
State/province [44] 0 0
Hokkaido
Country [45] 0 0
Japan
State/province [45] 0 0
Hyogo
Country [46] 0 0
Japan
State/province [46] 0 0
Kumamoto
Country [47] 0 0
Japan
State/province [47] 0 0
Osaka
Country [48] 0 0
Japan
State/province [48] 0 0
Tokyo
Country [49] 0 0
Japan
State/province [49] 0 0
Fukuoka
Country [50] 0 0
Latvia
State/province [50] 0 0
Riga
Country [51] 0 0
Latvia
State/province [51] 0 0
Ventspils
Country [52] 0 0
Mexico
State/province [52] 0 0
Ciudad DE Mexico
Country [53] 0 0
Mexico
State/province [53] 0 0
Ciudad DE México
Country [54] 0 0
Mexico
State/province [54] 0 0
Coahuila
Country [55] 0 0
Mexico
State/province [55] 0 0
Yucatan
Country [56] 0 0
Mexico
State/province [56] 0 0
Chihuahua
Country [57] 0 0
Mexico
State/province [57] 0 0
Veracruz
Country [58] 0 0
Poland
State/province [58] 0 0
Bialystok
Country [59] 0 0
Poland
State/province [59] 0 0
Bydgoszcz
Country [60] 0 0
Poland
State/province [60] 0 0
Chorzow
Country [61] 0 0
Poland
State/province [61] 0 0
Czestochowa
Country [62] 0 0
Poland
State/province [62] 0 0
Gdansk
Country [63] 0 0
Poland
State/province [63] 0 0
Katowice
Country [64] 0 0
Poland
State/province [64] 0 0
Krakow
Country [65] 0 0
Poland
State/province [65] 0 0
Lodz
Country [66] 0 0
Poland
State/province [66] 0 0
Ostrowiec Swietokrzyski
Country [67] 0 0
Poland
State/province [67] 0 0
Piotrkow Trybunalski
Country [68] 0 0
Poland
State/province [68] 0 0
Poznan
Country [69] 0 0
Poland
State/province [69] 0 0
Warszawa
Country [70] 0 0
Poland
State/province [70] 0 0
Wroclaw
Country [71] 0 0
Spain
State/province [71] 0 0
LAS Palmas
Country [72] 0 0
Spain
State/province [72] 0 0
Alicante
Country [73] 0 0
Spain
State/province [73] 0 0
Barcelona
Country [74] 0 0
Spain
State/province [74] 0 0
Madrid
Country [75] 0 0
Spain
State/province [75] 0 0
Zaragoza
Country [76] 0 0
Taiwan
State/province [76] 0 0
Taichung
Country [77] 0 0
Taiwan
State/province [77] 0 0
Taipei
Country [78] 0 0
United Kingdom
State/province [78] 0 0
South Yorkshire

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to \<18 years of age with moderate to severe AD.
Trial website
https://clinicaltrials.gov/study/NCT03796676
Trial related presentations / publications
Cork MJ, McMichael A, Teng J, Valdez H, Rojo R, Chan G, Zhang F, Myers DE, DiBonaventura M. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):422-433. doi: 10.1111/jdv.17792. Epub 2021 Dec 4.
Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, Yao Z, Takahashi H, Barbarot S, Feeney C, Zhang F, DiBonaventura M, Rojo R, Valdez H, Chan G. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial. JAMA Dermatol. 2021 Oct 1;157(10):1165-1173. doi: 10.1001/jamadermatol.2021.2830. Erratum In: JAMA Dermatol. 2021 Oct 1;157(10):1246. doi: 10.1001/jamadermatol.2021.4398.
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03796676